These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
96 related articles for article (PubMed ID: 7580832)
1. Production in rabbits of high levels of anti-HIV-1 gp160 antibodies. Relyveld E; Bizzini B Cell Mol Biol (Noisy-le-grand); 1995 May; 41(3):389-93. PubMed ID: 7580832 [TBL] [Abstract][Full Text] [Related]
3. HIV experimental vaccines based on the iscom technology using envelope and GAG gene products. Akerblom L; Nara P; Dunlop N; Putney S; Morein B Biotechnol Ther; 1993; 4(3-4):145-61. PubMed ID: 8292967 [TBL] [Abstract][Full Text] [Related]
4. Characterization of a vaccinia-derived recombinant HIV-1 gp160 candidate vaccine and its immunogenicity in chimpanzees. Barrett N; Eder G; Dorner F Biotechnol Ther; 1991; 2(1-2):91-106. PubMed ID: 1845126 [TBL] [Abstract][Full Text] [Related]
5. Adjuvanticity of stearyl tyrosine on the antibody response to peptide 503-535 from HIV gp160. Nixon A; Zaghouani H; Penney CL; Lacroix M; Dionne G; Anderson SA; Kennedy RC; Bona CA Viral Immunol; 1992; 5(2):141-50. PubMed ID: 1616585 [TBL] [Abstract][Full Text] [Related]
6. Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies. Deml L; Schirmbeck R; Reimann J; Wolf H; Wagner R Virology; 1997 Aug; 235(1):26-39. PubMed ID: 9300034 [TBL] [Abstract][Full Text] [Related]
7. HIV-1 recombinant gp160 vaccine given in accelerated dose schedules. Clin Exp Immun 1994;98:178-84. DePalma L Pediatr AIDS HIV Infect; 1995 Apr; 6(2):97-8. PubMed ID: 11361387 [No Abstract] [Full Text] [Related]
8. Cross-neutralizing antibodies to HIV-1 in mice after immunization with gp160 iscoms. Dissection of the immune response. Akerblom L; Nara P; Dunlop N; Morein B AIDS Res Hum Retroviruses; 1991 Jul; 7(7):621-7. PubMed ID: 1768464 [TBL] [Abstract][Full Text] [Related]
9. Effect of nonprotective vaccination on antibody response to subsequent human immunodeficiency virus infection. Pincus SH; Messer KG; Hu SL J Clin Invest; 1994 Jan; 93(1):140-6. PubMed ID: 8282780 [TBL] [Abstract][Full Text] [Related]
10. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Dis Markers; 1991; 9(1):51. PubMed ID: 1742945 [No Abstract] [Full Text] [Related]
11. Adjuvanticity of stearyl tyrosine on the antibody response to peptide 503-535 from HIV gp160. Bona C; Nixon A; Kennedy R; Zaghouani H AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1377. PubMed ID: 1466959 [No Abstract] [Full Text] [Related]
12. Anti-CD4 anti-idiotype antibodies in volunteers immunized with rgp160 of HIV-1 or infected with HIV-1. Keay S; Tacket CO; Murphy JR; Handwerger BS AIDS Res Hum Retroviruses; 1992 Jun; 8(6):1091-8. PubMed ID: 1503823 [TBL] [Abstract][Full Text] [Related]
13. Cross-neutralizing antibodies in rabbits immunized with HIV-1 gp160 purified from simian cells infected with a recombinant vaccinia virus. Klaniecki J; Dykers T; Travis B; Schmitt R; Wain M; Watson A; Sridhar P; McClure J; Morein B; Ulrich JT AIDS Res Hum Retroviruses; 1991 Oct; 7(10):791-8. PubMed ID: 1742074 [TBL] [Abstract][Full Text] [Related]
14. Immunization of chimpanzees with the HIV-1 glycoprotein gp160 induces long-lasting T-cell memory. Mannhalter JW; Pum M; Wolf HM; Küpcü Z; Barrett N; Dorner F; Eder G; Eibl MM AIDS Res Hum Retroviruses; 1991 May; 7(5):485-93. PubMed ID: 1714748 [TBL] [Abstract][Full Text] [Related]
15. Effects of adjuvants and multiple antigen peptides on humoral and cellular immune responses to gp160 of HIV-1. Levi M; Rudén U; Birx D; Loomis L; Redfield R; Lövgren K; Akerblom L; Sandström E; Wahren B J Acquir Immune Defic Syndr (1988); 1993 Aug; 6(8):855-64. PubMed ID: 8315572 [TBL] [Abstract][Full Text] [Related]
16. Immunization with recombinant gp160 prolongs the survival of HIV-1 transgenic mice. Shirai A; Klinman DM AIDS Res Hum Retroviruses; 1993 Oct; 9(10):979-83. PubMed ID: 8280480 [TBL] [Abstract][Full Text] [Related]
17. High-titer HIV-1 neutralizing antibody response of rhesus macaques to gp160 and env peptides. Ronco J; Dedieu JF; Marie FN; Pinter A; Kaczorek M; Girard M AIDS Res Hum Retroviruses; 1992 Jun; 8(6):1117-23. PubMed ID: 1503824 [TBL] [Abstract][Full Text] [Related]
18. Response of monkeys to vaccination with recombinant vaccinia virus which coexpress HIV gp160 and human interleukin-2. Ruby J; Brinkman C; Jones S; Ramshaw I Immunol Cell Biol; 1990 Apr; 68 ( Pt 2)():113-7. PubMed ID: 2200748 [TBL] [Abstract][Full Text] [Related]
19. Oral priming followed by parenteral immunization with HIV-immunosomes induce HIV-1-specific salivary and circulatory IgA in mice and rabbits. Thibodeau L; Tremblay C; Lachapelle L AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1379. PubMed ID: 1466960 [No Abstract] [Full Text] [Related]
20. A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. Military Medical Consortium for Applied Retroviral Research. Redfield RR; Birx DL; Ketter N; Tramont E; Polonis V; Davis C; Brundage JF; Smith G; Johnson S; Fowler A N Engl J Med; 1991 Jun; 324(24):1677-84. PubMed ID: 1674589 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]